Higher expression of monocyte chemotactic protein 1 in mild COVID-19 patients might be correlated with inhibition of Type I IFN signaling
Open Access
- 7 January 2021
- journal article
- research article
- Published by Springer Nature in Virology Journal
- Vol. 18 (1) , 1-7
Abstract
Background: Chemokine levels in severe coronavirus disease 2019 (COVID-19) patients have been shown to be markedly elevated. But the role of chemokines in mild COVID-19 has not yet been established. According to the epidemiological statistics, most of the COVID-19 cases in Shiyan City, China, have been mild. The purpose of this study was to evaluate the level of chemokines in mild COVID-19 patients and explore the correlation between chemokines and host immune response. Methods: In this study, we used an enzyme-linked immunosorbent assay to detect serum levels of chemokines in COVID-19 patients in Shiyan City. Expression of chemokine receptors and of other signaling molecules was measured by real-time polymerase chain reaction. Results: We first demonstrated that COVID-19 patients, both sever and mild cases, are characterized by higher level of chemokines. Specifically, monocyte chemotactic protein 1 (MCP-1) is expressed at higher levels both in severe and mild cases of COVID-19. The receptor of MCP-1, C-C chemokine receptor type 2, was expressed at higher levels in mild COVID-19 patients. Finally, we observed a significant negative correlation between expression levels of interferon (IFN) regulatory factor 3 (IRF3) and serum levels of MCP-1 in mild COVID-19 patients. Conclusion: Higher expression of MCP-1 in mild COVID-19 patients might be correlated with inhibition of IFN signaling. The finding adds to our understanding of the immunopathological mechanisms of severe acute respiratory syndrome coronavirus 2 infection and provides potential therapeutic targets and strategies.Keywords
All Related Versions
Funding Information
- Emergency Research Project for COVID-19 of Shiyan City (20Y01)
- Emergency Research Project for COVID-19 of Hubei University of Medicine (2020XGFYZR02, 2020XGFYZR03)
- The Principal Grant of Hubei University of Medicine (HBMUPI201804)
- Hubei Provincial Natural Science Foundation (2017CFB238)
This publication has 31 references indexed in Scilit:
- International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine ReceptorsPharmacological Reviews, 2014
- IFNβ autocrine feedback is required to sustain TLR induced production of MCP‐1 in macrophagesFEBS Letters, 2013
- A diverse range of gene products are effectors of the type I interferon antiviral responseNature, 2011
- Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patientsVirus Research, 2009
- Monocyte Chemoattractant Protein-1 (MCP-1): An OverviewJournal of Interferon & Cytokine Research, 2009
- Chemokine Signaling via the CXCR2 Receptor Reinforces SenescenceCell, 2008
- Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndromeRespirology, 2006
- Type 1 Interferons and the Virus-Host Relationship: A Lesson in DétenteScience, 2006
- Interferons, interferon‐like cytokines, and their receptorsImmunological Reviews, 2004
- Chemokine receptors: multifaceted therapeutic targetsNature Reviews Immunology, 2002